Eloxx Pharmaceuticals Inc (OTCPK:ELOX)
$ 0.68557 -0.05443 (-7.36%) Market Cap: 2.15 Mil Enterprise Value: 3.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Eloxx Pharmaceuticals Inc To Host Investor and Analyst Call on Alport Syndrome Transcript

Jun 27, 2023 / 03:30PM GMT
Release Date Price: $4.06 (+2.53%)
Rachel Lennon
The University of Manchester - Professor of Nephrology

Ladies and gentlemen, thank you for standing by. And welcome to the Eloxx Pharmaceuticals webcast to discuss the unmet need in Alport syndrome and additional clinical data results from the topline ELX-02 Phase 2 clinical trial.

(Operator Instructions) I would now like to turn the conference over to your first speaker today, Sumit Aggarwal, Eloxx's President and Chief Executive Officer. Sumit, you may begin.

Sumit Aggarwal
Eloxx Pharmaceuticals, Inc. - President & CEO

Thank you. Welcome, everyone, listening to the call today. We're excited about sharing the Alport syndrome overview and our results in ELX-02. This is a very exciting time for Eloxx as we plan our pivotal study in Alport.

On the next slide, you see that we're going to be making some forward-looking statements. Please refer to our SEC documents for detailed risk factors.

Now, turning over to the agenda on the next slide, we're really excited to have Professors Rachel Lennon and Detlef BÃ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot